Literature DB >> 33910853

Case Series of Pleomorphic Carcinoma of the Lung Treated With Immune Checkpoint Inhibitors.

Kana Hayashi1, Kotaro Tokui1, Minehiko Inomata2, Kenji Azechi1, Isami Mizushima1, Naoki Takata1, Chihiro Taka1, Seisuke Okazawa1, Kenta Kambara1, Shingo Imanishi1, Toshiro Miwa1, Ryuji Hayashi3, Shoko Matsui1, Satoshi Nomura4, Kazuyuki Tobe1.   

Abstract

AIM: We report, herein, three cases of pleomorphic carcinoma of the lung treated with immune checkpoint inhibitors. Case 1: A 73-year-old man was diagnosed as having pleomorphic carcinoma of the lung and treated with pembrolizumab alone. However, he showed no response and died 4 months after the initiation of the treatment. Case 2: A 66-year-old man was diagnosed as having pleomorphic carcinoma of the lung. He was started on a combination regimen of pembrolizumab plus carboplatin plus nab-paclitaxel, and a remarkable response was observed. Case 3: A 49-year-old man was diagnosed as having pleomorphic carcinoma of the lung. He was started on pembrolizumab monotherapy as second-line treatment. Eleven months after the treatment initiation, computed tomography revealed the decrease of tumor diameter.
CONCLUSION: Immune checkpoint inhibitor therapy is expected to improve the prognosis of patients with pleomorphic carcinoma of the lung. Copyright
© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Immune checkpoint inhibitor; pembrolizumab; pleomorphic carcinoma; sarcomatoid carcinoma

Mesh：

Substances：

Year:  2021        PMID： 33910853      PMCID： PMC8193335          DOI： 10.21873/invivo.12428

Source DB:  PubMed          Journal:  In Vivo        ISSN： 0258-851X            Impact factor:   2.155


  27 in total

1.  Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

Authors:  Leena Gandhi; Delvys Rodríguez-Abreu; Shirish Gadgeel; Emilio Esteban; Enriqueta Felip; Flávia De Angelis; Manuel Domine; Philip Clingan; Maximilian J Hochmair; Steven F Powell; Susanna Y-S Cheng; Helge G Bischoff; Nir Peled; Francesco Grossi; Ross R Jennens; Martin Reck; Rina Hui; Edward B Garon; Michael Boyer; Belén Rubio-Viqueira; Silvia Novello; Takayasu Kurata; Jhanelle E Gray; John Vida; Ziwen Wei; Jing Yang; Harry Raftopoulos; M Catherine Pietanza; Marina C Garassino
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

2.  Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.

Authors:  Stephen J Bagley; Shawn Kothari; Charu Aggarwal; Joshua M Bauml; Evan W Alley; Tracey L Evans; John A Kosteva; Christine A Ciunci; Peter E Gabriel; Jeffrey C Thompson; Susan Stonehouse-Lee; Victoria E Sherry; Elizabeth Gilbert; Beth Eaby-Sandy; Faith Mutale; Gloria DiLullo; Roger B Cohen; Anil Vachani; Corey J Langer
Journal:  Lung Cancer       Date:  2017-01-25       Impact factor: 5.705

3.  Concurrent combination of irradiation and immune checkpoint inhibitor for recurrent pleomorphic carcinoma of the lung.

Authors:  Ken Kodama; Tomohiro Maniwa; Yukio Kimura; Yuriko Yagi; Yoko Yamamoto; Toshika Ohkawa; Masashi Takeda; Hiroki Kishima; Genju Koh; Takamasa Toyofuku
Journal:  Int Cancer Conf J       Date:  2017-12-15

4.  Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor.

Authors:  Minehiko Inomata; Tomonobu Kado; Seisuke Okazawa; Shingo Imanishi; Chihiro Taka; Kenta Kambara; Takahiro Hirai; Hiroaki Tanaka; Kotaro Tokui; Kana Hayashi; Toshiro Miwa; Ryuji Hayashi; Shoko Matsui; Kazuyuki Tobe
Journal:  Anticancer Res       Date:  2019-12       Impact factor: 2.480

5.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

6.  A high number of PD-L1+ CD14+ monocytes in peripheral blood is correlated with shorter survival in patients receiving immune checkpoint inhibitors.

Authors:  Kiyohiro Ando; Kazuyuki Hamada; Midori Shida; Ryotaro Ohkuma; Yutaro Kubota; Atsushi Horiike; Hiroto Matsui; Tomoyuki Ishiguro; Yuya Hirasawa; Hirotsugu Ariizumi; Makoto Watanabe; Rie Onoue; Junji Tsurutani; Kiyoshi Yoshimura; Takuya Tsunoda; Shinichi Kobayashi; Satoshi Wada
Journal:  Cancer Immunol Immunother       Date:  2020-08-05       Impact factor: 6.968

7.  Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas.

Authors:  Sehui Kim; Moon-Young Kim; Jaemoon Koh; Heounjeong Go; Dong Soo Lee; Yoon Kyung Jeon; Doo Hyun Chung
Journal:  Eur J Cancer       Date:  2015-08-29       Impact factor: 9.162

8.  Predictive Factors for Poor Progression-free Survival in Patients with Non-small Cell Lung Cancer Treated with Nivolumab.

Authors:  Yoshihiko Taniguchi; Akihiro Tamiya; Syun-Ichi Isa; Kenji Nakahama; Kyoichi Okishio; Takayuki Shiroyama; Hidekazu Suzuki; Takako Inoue; Motohiro Tamiya; Tomonori Hirashima; Fumio Imamura; Shinji Atagi
Journal:  Anticancer Res       Date:  2017-10       Impact factor: 2.480

9.  Pulmonary pleomorphic carcinoma with pseudoprogression during nivolumab therapy and the usefulness of tumor markers: A case report.

Authors:  Akihiro Yoshimura; Chieko Takumi; Taisuke Tsuji; Ryosuke Hamashima; Shinsuke Shiotsu; Tatsuya Yuba; Yoji Urata; Noriya Hiraoka
Journal:  Clin Case Rep       Date:  2018-05-29

10.  Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

Authors:  Mark A Socinski; Robert M Jotte; Federico Cappuzzo; Francisco Orlandi; Daniil Stroyakovskiy; Naoyuki Nogami; Delvys Rodríguez-Abreu; Denis Moro-Sibilot; Christian A Thomas; Fabrice Barlesi; Gene Finley; Claudia Kelsch; Anthony Lee; Shelley Coleman; Yu Deng; Yijing Shen; Marcin Kowanetz; Ariel Lopez-Chavez; Alan Sandler; Martin Reck
Journal:  N Engl J Med       Date:  2018-06-04       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.